onc brain

The longer read

The value of OLIGOMA is not the hazard ratio. It is that a randomised trial in breast cancer specifically now points the same direction as the MDT literature built largely on prostate and mixed-histology cohorts, and that it did so with the systemic regimen fixed by tumour board before randomisation. That design choice matters more than it reads. The recurring criticism of metastasis-directed therapy trials is that the ablative arm attracts more attentive systemic management, and pre-specifying the regimen at the board removes the most obvious route for that confounding. What is left in the comparison is the radiotherapy.

Against that, the accrual failure is severe and should move a reader's confidence a long way. Recruitment closed below 20% of the original target and below 40% of the amended one, leaving 87 pts and a confidence interval running from 0.25 to 0.91. An interval whose upper bound sits that close to 1 is compatible with a benefit far smaller than the point estimate implies, and a 15-month median separation generated by roughly forty events per arm is the kind of number that shrinks when the sample grows. The honest reading is that the trial establishes a direction and leaves the magnitude to the eight trials still accruing.

The population narrows the claim further. Most pts were ER/PR positive, HER2 negative, on first-line therapy, with 1-3 lesions and two-thirds of those lesions in bone. This is the most favourable biology in metastatic breast cancer and the setting where systemic control is already strongest, which cuts two ways for a radiation oncologist. Indolent bone-dominant disease is where ablation is technically easiest and least toxic, so the tolerability finding transfers well. But it is also where progression is slowest and where a PFS endpoint is most sensitive to which lesions were imaged and how often, and progression-free survival remains a surrogate. Whether treating all lesions changes survival in this group is not addressed here.

The part of the design a radiation oncologist should hold onto is the eligibility rule rather than the effect size. RT was required to every metastatic lesion, and pts who needed palliative radiotherapy to all their sites were excluded. This is comprehensive ablation of a low-burden, largely asymptomatic disease state, not consolidation of a dominant site in someone already symptomatic. A pt with five lesions who is being irradiated for pain is outside what was tested, and the trial gives no support for extrapolating to them. Dose, fractionation and target definition are not in the source material presented, which is the single largest gap for anyone trying to reproduce this in their own department, since bone metastasis ablation covers a wide range of practice.

The co-primary quality-of-life result deserves its own weight. Treating five separate sites carries an obvious burden argument against it, and the 12-week comparison stayed within the prespecified non-inferiority margin, so the burden argument loses its short-term footing. Twelve weeks will not detect late effects in a population living beyond thirty months, and the trial's own investigators frame the QoL claim as short-term. For now the defensible position is that comprehensive ablation is worth offering and worth discussing as unsettled, not that it is established care.